Are you Dr. Farooqui?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 37 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1801 W Taylor St
Outpatient Care Center (Mc 771)
Chicago, IL 60612Phone+1 312-996-2242- Is this information wrong?
Summary
- Dr. Mohammed Farooqui, DO is an oncologist in Chicago, Illinois. He is currently licensed to practice medicine in Illinois.
Education & Training
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 2008 - 2011
University of Illinois College of Medicine at ChicagoResidency, Internal Medicine, 2005 - 2008
Texas College of Osteopathic MedicineClass of 2005
Certifications & Licensure
IL State License 2008 - 2026
Clinical Trials
- Ofatumumab-based Induction Chemoimmunotherapy in Previously Untreated Patients With CLL/SLL Start of enrollment: 2010 Jul 01
Publications & Presentations
PubMed
- Risk-adapted, ofatumumab-based chemoimmunotherapy and consolidation in treatment-naïve chronic lymphocytic leukemia: a phase 2 study., , , , , , , , , , , , , , , , , , , , , , , > ;Leukemia & Lymphoma. 2021 Mar 2
- 54 citationsClinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib., , , , , , , , , , , , , , , , , , , > ;Blood. 2020 Jul 2
- 3 citationsRichter transformation to Hodgkin lymphoma on Bruton's tyrosine kinase inhibitor therapy.Alankrita Taneja, Jade Jones, Stefania Pittaluga, Irina Maric, Mohammed Farooqui, Inhye E. Ahn, Clare Sun> ;Leukemia & Lymphoma. 2019 Jan 28
- Join now to see all
